This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Novo-Catalent deal could hurt smaller drugmakers who lack strong access to contract manufacturing, Roche CEO says

( October 23, 2024, 18:46 GMT | Official Statement) -- MLex Summary: Blockbuster obesity drug manufacturer Novo Holding's proposed acquisition of Catalent — a medical contract development and manufacturing organization, or CDMO, — "doesn't make sense" from a competition standpoint and is likely to elicit objections from "antitrust authorities who want competition,"  Roche CEO Thomas Schinecker said during an earnings call. According to Schinecker, "in general, if companies start buying up CMOs, that will limit the amount of competition that there can be." Excerpt from earnings call follows below:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login